CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
C4 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.89+0.13 (+4.52%)
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.6%
118M of 123M shares
Institutional holders
148
52 new, 27 sold out
Net institutional buying
33M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $22.20K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Morgan Stanley | 8,862,002 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 7,678,906 | 6.90% | 13G (passive) | Jun 30, 2026 |
| Squadron Master Fund LP | 7,600,000 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Lynx1 Capital Management LP | 7,098,133 | 7.30% | 13G (passive) amendment | Dec 31, 2025 |
| BCLS II Equity Opportunities, LP | 6,060,000 | 6.25% | 13G (passive) | Oct 17, 2025 |
| Betta Investment (Hong Kong) Limited | 5,567,928 | 8.10% | 13G (passive) | Jan 4, 2024 |
| Matthew Sesterhenn | 5,550,000 | 5.00% | 13G (passive) | May 12, 2026 |
| Sirenia Capital Management LP | 23,505,000 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Steven A. Cohen | 22,647,647 | 9.90% | 13G (passive) | Oct 17, 2025 |
| Weston Nichols | 15,423,691 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah | 11,383,696 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Soleus Capital, LLC | 10,361,860 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CCCC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 8,867,338 | 7.21% | $41.41M | −205,062 | 0.00% |
| Ra Capital Management, L.P. | 8,000,000 | 6.50% | $37.36M | – | 0.32% |
| BlackRock, Inc. | 7,896,718 | 6.42% | $36.88M | +5,848,192 | 0.00% |
| Lynx1 Capital Management LP | 7,326,691 | 5.96% | $34.22M | +327,789 | 3.95% |
| Squadron Capital Management LLC | 7,200,000 | 5.85% | $33.62M | +4,950,000 | 10.43% |
| Bain Capital Life Sciences Investors, LLC | 7,171,910 | 5.83% | $33.49M | – | 1.99% |
| JPMorgan Chase & Co | 4,747,424 | 3.86% | $20.65M | +1,524,370 | 0.00% |
| Vanguard Capital Management LLC | 4,417,731 | 3.59% | $20.63M | +555,879 | 0.00% |
| Citadel Advisors LLC | 4,187,580 | 3.40% | $19.56M | +1,676,565 | 0.00% |
| Goldman Sachs Group Inc | 3,530,991 | 2.87% | $16.49M | +1,143,613 | 0.00% |
| Wasatch Advisors LP | 3,522,644 | 2.86% | $16.45M | +560,883 | 0.11% |
| Two Sigma Investments, LP | 3,469,707 | 2.82% | $16.20M | +434,073 | 0.01% |
| Soleus Capital Management, L.P. | 3,377,981 | 2.75% | $15.78M | −425,961 | 0.54% |
| Silverarc Capital Management, LLC | 3,032,060 | 2.46% | $14.16M | +1,120,275 | 1.47% |
| Bank Of America Corp /De/ | 2,656,359 | 2.16% | $12.41M | +297,118 | 0.00% |
| Geode Capital Management, LLC | 2,522,163 | 2.05% | $11.78M | +1,571,120 | 0.00% |
| Ikarian Capital, LLC | 2,433,000 | 1.98% | $11.36M | New | 1.22% |
| State Street Corp | 2,115,621 | 1.72% | $9.88M | +1,732,648 | 0.00% |
| Acadian Asset Management LLC | 1,806,199 | 1.47% | $8.43K | −84,715 | 0.01% |
| Candriam S.C.A. | 1,796,937 | 1.46% | $8.38M | New | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 148 | 118M | 95.6% | 52 / 53 | 28 / 27 | 41M | 9M |
| Q1 2026 | 123 | 85M | 69.0% | 34 / 41 | 32 / 11 | 24M | 14M |
| Q4 2025 | 101 | 80M | 64.9% | 24 / 44 | 20 / 16 | 38M | 11M |
| Q3 2025 | 97 | 53M | 42.7% | 21 / 27 | 37 / 26 | 6M | 8M |
| Q2 2025 | 102 | 55M | 44.6% | 26 / 32 | 32 / 39 | 7M | 16M |
| Q1 2025 | 115 | 64M | 52.1% | 27 / 40 | 28 / 23 | 8M | 8M |
| Q4 2024 | 113 | 64M | 52.3% | 25 / 37 | 34 / 29 | 9M | 9M |
| Q3 2024 | 118 | 64M | 52.2% | 31 / 37 | 30 / 26 | 17M | 9M |
| Q2 2024 | 115 | 61M | 49.5% | 35 / 31 | 35 / 25 | 15M | 14M |
| Q1 2024 | 106 | 59M | 48.2% | 39 / 29 | 27 / 25 | 23M | 11M |
| Q4 2023 | 92 | 47M | 38.4% | 31 / 29 | 23 / 22 | 22M | 9M |
| Q3 2023 | 83 | 35M | 28.1% | 7 / 30 | 32 / 23 | 6M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CCCC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,264,924 | 2.65% | $15.25M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,595,893 | 2.11% | $12.12M | 0.01% | Jun 30, 2026 |
| Wasatch Ultra Growth Fund | 2,503,777 | 2.04% | $11.69M | 2.53% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,110,012 | 0.90% | $3.86M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,047,349 | 0.85% | $4.89M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 931,903 | 0.76% | $4.35M | 0.03% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 780,673 | 0.63% | $3.65M | 0.06% | Jun 30, 2026 |
| Wasatch Micro Cap Fund | 761,872 | 0.62% | $3.56M | 0.53% | Jun 30, 2026 |
| iShares Biotechnology ETF | 707,427 | 0.58% | $3.30M | 0.04% | Jun 30, 2026 |
| JNL Multi-Manager Small Cap Value Fund | 633,783 | 0.52% | $2.96M | 0.15% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 415,948 | 0.34% | $1.82M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 377,039 | 0.31% | $1.65M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 340,711 | 0.28% | $1.59M | 0.10% | Jun 30, 2026 |
| Small Cap Value Fund | 307,074 | 0.25% | $1.43M | 0.21% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 246,397 | 0.20% | $857.46K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew Hirsch | President & CEO, Director | 1,083,991 | 0.88% | Feb 18, 2026 |
| Kendra Adams | Chief Financial Officer | 385,098 | 0.31% | Sep 21, 2026 |
| Leonard Reyno | Chief Medical Officer | 372,406 | 0.30% | Jul 13, 2026 |
| Kelly Schick | Chief People Officer | 299,881 | 0.24% | Feb 18, 2026 |
| Mark Mossler | Chief Accounting Officer | 71,916 | 0.06% | Feb 18, 2026 |
| Paige Mahaney | Chief Scientific Officer | 336,910 | 0.27% | Feb 18, 2026 |
| Scott N. Boyle | Chief Business Officer | 306,070 | 0.25% | Feb 18, 2026 |
| Jolie Siegel | Chief Legal Officer | 107,939 | 0.09% | Feb 18, 2025 |
| Kenneth Carl Anderson | Director | 358,235 | 0.29% | Jul 2, 2026 |
| Donna Roy Grogan | Director | 74,853 | 0.06% | Jul 2, 2026 |
| Owen Hughes | Director | – | – | Jun 26, 2026 |
| Utpal Koppikar | Director | 5,667 | 0.00% | Jun 26, 2026 |
| Steven L. Hoerter | Director | – | – | Jun 26, 2026 |
| Laura Bessen | Director | – | – | Jun 26, 2026 |
| Ronald Harold Wilfred Cooper | Director | – | – | Jun 26, 2026 |
| Stephen Fawell | Director | – | – | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kendra Adams Chief Financial Officer | Sep 18, 2026 | Option exercise | +6,250 | – | – | 385,098 |
| Kendra Adams Chief Financial Officer | Sep 18, 2026 | Tax withholding | −2,775 | $3.39 | $9.41K | 382,323 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2026 | Tax withholding | −7,397 | $4.06 | $30.03K | 372,406 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2026 | Option exercise | +15,325 | – | – | 379,803 |
| Donna Roy Grogan Director | Jul 1, 2026 | Award | +3,341 | $4.34 | $14.50K | 74,853 |
| Kenneth Carl Anderson Director | Jul 1, 2026 | Award | +2,650 | $4.34 | $11.50K | 71,950 |
| Kenneth Carl Anderson Director | Jun 1, 2026 | Option exercise | +1,070 | $2.11 | $2.26K | 69,300 |
| Donna Roy Grogan Director | Apr 1, 2026 | Award | +5,370 | $2.70 | $14.50K | 71,512 |
| Kenneth Carl Anderson Director | Apr 1, 2026 | Award | +4,259 | $2.70 | $11.50K | 68,230 |
| Andrew Hirsch President & CEO, Director | Feb 15, 2026 | Option exercise | +20,400 | – | – | 1,083,991 |
| Andrew Hirsch President & CEO, Director | Feb 15, 2026 | Tax withholding | −9,057 | $1.89 | $17.12K | 1,074,934 |
| Mark Mossler Chief Accounting Officer | Feb 14, 2026 | Tax withholding | −3,268 | $1.89 | $6.18K | 71,916 |
| Mark Mossler Chief Accounting Officer | Feb 14, 2026 | Option exercise | +9,420 | – | – | 75,184 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2026 | Option exercise | +20,950 | – | – | 306,070 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2026 | Tax withholding | −7,269 | $1.89 | $13.74K | 298,801 |
| Paige Mahaney Chief Scientific Officer | Feb 14, 2026 | Tax withholding | −2,446 | $1.89 | $4.62K | 336,910 |
| Paige Mahaney Chief Scientific Officer | Feb 14, 2026 | Option exercise | +7,050 | – | – | 339,356 |
| Kendra Adams Chief Financial Officer | Feb 14, 2026 | Option exercise | +30,950 | – | – | 400,479 |
| Kendra Adams Chief Financial Officer | Feb 14, 2026 | Tax withholding | −15,381 | $1.89 | $29.07K | 385,098 |
| Kelly Schick Chief People Officer | Feb 14, 2026 | Tax withholding | −7,269 | $1.89 | $13.74K | 299,881 |
| Kelly Schick Chief People Officer | Feb 14, 2026 | Option exercise | +20,950 | – | – | 307,150 |
| Leonard Reyno Chief Medical Officer | Feb 14, 2026 | Option exercise | +30,950 | – | – | 396,382 |
| Leonard Reyno Chief Medical Officer | Feb 14, 2026 | Tax withholding | −16,579 | $1.89 | $31.33K | 379,803 |
| Andrew Hirsch President & CEO, Director | Feb 14, 2026 | Option exercise | +81,725 | – | – | 1,123,145 |
| Andrew Hirsch President & CEO, Director | Feb 14, 2026 | Tax withholding | −39,154 | $1.89 | $74.00K | 1,083,991 |
| Mark Mossler Chief Accounting Officer | Feb 13, 2026 | Award | +56,980 | – | – | 75,184 |
| Scott N. Boyle Chief Business Officer | Feb 13, 2026 | Tax withholding | −1,735 | $1.89 | $3.28K | 306,070 |
| Scott N. Boyle Chief Business Officer | Feb 13, 2026 | Option exercise | +5,000 | – | – | 307,805 |
| Scott N. Boyle Chief Business Officer | Feb 13, 2026 | Award | +200,000 | – | – | 307,805 |
| Paige Mahaney Chief Scientific Officer | Feb 13, 2026 | Award | +240,000 | – | – | 339,356 |
| Kendra Adams Chief Financial Officer | Feb 13, 2026 | Option exercise | +3,750 | – | – | 402,342 |
| Kendra Adams Chief Financial Officer | Feb 13, 2026 | Award | +240,000 | – | – | 402,342 |
| Kendra Adams Chief Financial Officer | Feb 13, 2026 | Tax withholding | −1,863 | $1.89 | $3.52K | 400,479 |
| Kelly Schick Chief People Officer | Feb 13, 2026 | Tax withholding | −1,735 | $1.89 | $3.28K | 307,150 |
| Kelly Schick Chief People Officer | Feb 13, 2026 | Option exercise | +5,000 | – | – | 308,885 |
| Kelly Schick Chief People Officer | Feb 13, 2026 | Award | +200,000 | – | – | 308,885 |
| Leonard Reyno Chief Medical Officer | Feb 13, 2026 | Award | +240,000 | – | – | 396,382 |
| Andrew Hirsch President & CEO, Director | Feb 13, 2026 | Award | +700,000 | – | – | 1,123,145 |
| Leonard Reyno Chief Medical Officer | Jan 16, 2026 | Sale | −10,000 | $2.22 | $22.20K | 156,382 |
| Kenneth Carl Anderson Director | Jan 2, 2026 | Award | +5,958 | $1.93 | $11.50K | 146,532 |
| Donna Roy Grogan Director | Jan 2, 2026 | Award | +7,513 | $1.93 | $14.50K | 66,142 |
| Paige Mahaney Chief Scientific Officer | Oct 28, 2025 | Tax withholding | −5,644 | $2.58 | $14.56K | 99,356 |
| Paige Mahaney Chief Scientific Officer | Oct 28, 2025 | Option exercise | +19,200 | – | – | 105,000 |
| Donna Roy Grogan Director | Oct 1, 2025 | Award | +6,740 | $2.15 | $14.49K | 58,629 |
| Kenneth Carl Anderson Director | Oct 1, 2025 | Award | +5,349 | $2.15 | $11.50K | 140,574 |
| Kendra Adams Chief Financial Officer | Sep 18, 2025 | Tax withholding | −2,775 | $3.32 | $9.21K | 162,342 |
| Kendra Adams Chief Financial Officer | Sep 18, 2025 | Option exercise | +6,250 | – | – | 165,117 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2025 | Option exercise | +15,325 | – | – | 173,764 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2025 | Tax withholding | −7,382 | $1.99 | $14.69K | 166,382 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2025 | Tax withholding | −7,382 | $1.99 | $14.69K | 166,382 |
| Kenneth Carl Anderson Director | Jul 1, 2025 | Award | +7,616 | $1.51 | $11.50K | 135,225 |
| Donna Roy Grogan Director | Jul 1, 2025 | Award | +9,609 | $1.51 | $14.51K | 51,889 |
| Kenneth Carl Anderson Director | Apr 1, 2025 | Award | +7,841 | $1.44 | $11.29K | 127,609 |
| Donna Roy Grogan Director | Apr 1, 2025 | Award | +9,581 | $1.44 | $13.80K | 42,280 |
| Scott N. Boyle Chief Business Officer | Feb 18, 2025 | Sale(10b5-1 plan) | −669 | $3.15 | $2.11K | 107,805 |
| Andrew Hirsch President & CEO, Director | Feb 15, 2025 | Tax withholding | −9,370 | $3.18 | $29.80K | 423,145 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2025 | Tax withholding | −2,368 | $3.18 | $7.53K | 108,474 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2025 | Sale(10b5-1 plan) | −490 | $3.15 | $1.54K | 110,842 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2025 | Award | +56,500 | – | – | 111,332 |
| Paige Mahaney Chief Scientific Officer | Feb 14, 2025 | Award | +28,200 | – | – | 105,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mossler Mark Officer | Aug 14, 2026 | 4,139 | $17.60K | Aug 14, 2026 | Restricted Stock |
| Geldmacher Jay Former REZI CEO | Aug 14, 2026 | 82,563 | $1.90M | Aug 14, 2026 | Restricted Stock |
| Mossler Mark Officer | Aug 13, 2026 | 15,000 | $61.07K | Aug 13, 2026 | Stock Option Exercise |
| Mossler Mark Officer | Aug 12, 2026 | 19,519 | $76.68K | Aug 12, 2026 | Stock Option Exercise |
| Mossler Mark Former Section 16 Officer | May 28, 2026 | 9,087 | $35.48K | May 27, 2026 | Grant under Issuer's 2020 Equity Incentive Plan |
| M. Siegel Jolie Officer | Mar 9, 2026 | 101,175 | $378.85K | Mar 9, 2026 | Stock Option Exercise |
| Malcolm Salter Director | Nov 18, 2024 | 13,000 | $54.53K | Nov 18, 2024 | STOCK OPTION EXERCISE |
| Malcolm Salter Director | Oct 18, 2024 | 13,000 | $83.32K | Oct 18, 2024 | STOCK OPTION EXERCISE |
| Malcolm Salter Director | Oct 11, 2024 | 8,561 | $46.06K | Oct 11, 2024 | STOCK OPTION EXERCISE |